Bivalirudin Versus Heparin as an Antithrombotic Agent in Patients Who Undergo Percutaneous Saphenous Vein Graft Intervention With a Distal Protection Device

Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions, and data on its usage in saphenous vein graft interventions are limited. This retrospective, observational study evaluated the efficacy and safety of bivalirudin compared with...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2005-07, Vol.96 (1), p.67-70
Main Authors: Rha, Seung-Woon, Kuchulakanti, Pramod K., Pakala, Rajbabu, Cheneau, Edouard, Pinnow, Ellen, Torguson, Rebecca, Pichard, Augusto D., Satler, Lowell F., Suddath, William O., Kent, Kenneth M., Lindsay, Joseph, Waksman, Ron
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Anticoagulants - adverse effects
Anticoagulants - therapeutic use
Antithrombins
Biological and medical sciences
Blood vessels
Blood. Blood coagulation. Reticuloendothelial system
Cardiology. Vascular system
Comparative analysis
Coronary Artery Disease - surgery
Drug therapy
Female
Heparin - therapeutic use
Hirudins - adverse effects
Humans
Male
Medical sciences
Middle Aged
Peptide Fragments - adverse effects
Peptide Fragments - therapeutic use
Pharmaceuticals
Pharmacology. Drug treatments
Postoperative Complications - prevention & control
Recombinant Proteins - adverse effects
Recombinant Proteins - therapeutic use
Retrospective Studies
Saphenous Vein - transplantation
Skin & tissue grafts
Stents
Thrombosis - prevention & control
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions, and data on its usage in saphenous vein graft interventions are limited. This retrospective, observational study evaluated the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients who underwent saphenous vein graft intervention with distal protection devices. We found that bivalirudin use is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2005.02.047